CFC-Only Asthma Drugs Likely To Lose “Essential Use” Designation
Executive Summary
FDA is likely to initiate proceedings to revoke the "essential use" designation for remaining chlorofluorocarbon-propelled asthma drug products following a lack of strong support by FDA's Pulmonary-Allergy Drugs Advisory Committee for continued use of any of the productsYou may also be interested in...
FDA Proposes Elimination of Seven Metered-Dose Inhaler Compounds
FDA is proposing that seven drugs used in metered-dose inhalers no longer be considered essential for the treatment of asthma and chronic obstructive pulmonary disease. Without such status, the drugs will no longer be exempt from regulations banning the use of chlorofluorocarbons in aerosol containers and will have to come off the market
FDA Proposes Elimination of Seven Metered-Dose Inhaler Compounds
FDA is proposing that seven drugs used in metered-dose inhalers no longer be considered essential for the treatment of asthma and chronic obstructive pulmonary disease. Without such status, the drugs will no longer be exempt from regulations banning the use of chlorofluorocarbons in aerosol containers and will have to come off the market
Kos Azmacort HFA Submission In ’07 Could Lead To Removal Of CFC Version
Kos plans to submit an NDA for Azmacort HFA in the second half of 2007, which would likely lead to the removal of CFC-containing Azmacort
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: